New ValiMed(TM) Medication Validation System DemonstratesUSP < 797 > Compliance at ASHP Summer Meeting Baxa Corporation demonstrates the next-generation ValiMed System for medication safety at booth no. 729 at the American Society of Health-System Ph
ENGLEWOOD, Colo., June 26, 2006 /PRNewswire via COMTEX/ -- Baxa Corporation
announces the release of the next-generation ValiMed Medication Validation
System at the summer meeting of the American Society for Health-System
Pharmacists. The ValiMed System validates medications and concentrations;
allowing users to detect counterfeit products for brand protection, provide
quality assurance for compounded products, and detect narcotic loss. The ValiMed
System ensures patient safety in real time, by verifying that medications are
correctly compounded.
ValiMed features patent-pending technology that validates in seconds the
strength of compounded doses of high risk medications prior to dispensing.
Verification of compounding accuracy and sterilization is a requirement under
USP 27-NF 22 Chapter < 797 >, which regulates the compounding of sterile
products. The ValiMed System can play a key role in demonstrating the safety of
compounded sterile products (CSPs) under these requirements.
The updated version of the ValiMed System -- shown for the first time at the
ASHP meeting -- incorporates reports used to comply with USP 797 requirements.
It also features a modified disposable, requiring a reduced sample volume for
testing. "This next-generation ValiMed System addresses customer requests,"
notes Product Manager Mark Thrasher. "It's more robust and the smaller sample
requirement more easily accommodates current pharmacy work flows."
During the meeting, Baxa representatives will demonstrate the ValiMed System's
capabilities in their booth, number 729. Pharmacists will see first-hand how the
system ensures the accuracy of their compounded solutions and helps them meet
both USP 797 verification and JCAHO requirements for patient safety.
About Baxa Corporation
Baxa, a customer-focused medical device company, provides innovative,
solution-based technologies for fluid handling and delivery. Its systems and
devices promote the safe and efficient preparation, handling, packaging, and
administration of fluid medications. Privately held, Baxa Corporation has
subsidiaries and sales offices in Canada and the United Kingdom; direct
representation in Belgium, Denmark, Finland, France, Germany, Luxembourg and The
Netherlands; and distribution partners worldwide. Further information is
available at www.baxa.com.
About CDEX, Inc.
CDEX Inc. (OTC Bulletin Board: CEXI), the manufacturer of the ValiMed System, is
a technology development company focused on producing equipment that uses using
chemical detection and validation technologies. CDEX technology is focused
currently on two distinct areas: (i) identification of substances of concern
(e.g., explosives and illegal drugs); and (ii) validation of substances for
anti-counterfeiting, brand protection and quality assurance. CDEX is
headquartered in Rockville, Maryland, with a primary research and development
laboratory in Tucson, Arizona. For more information, visit www.cdex-inc.com and
www.valimed.com.
